ApprovedAnesthetic

Hold to activate 3D

Molecular

2.5% LIDOCAINE AND 2.5% PRILOCAINE

Formula Pending

Molecular Mass

N/A

CAS Registry

N/A

Risk Class

LOW

Last Audit

Jan 1, 2024

Research Abstract

Anesthetic medication

2.5% LIDOCAINE AND 2.5% PRILOCAINE is a anesthetic asset inside marketed initiatives, optimized for therapeutic and clinical research.

The dossier currently sits in approved with a low risk rating, meaning it is cleared for baseline monitoring protocols.

Supply records cite CAS N/A with updates logged 2024-01-01.

AI Analysis

Community Hub

Product Reviews

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Initiate Transfer Return to Index

Primary Vectors

TherapeuticClinical Research

Nomenclature

2.5% LIDOCAINE AND 2.5% PRILOCAINE

Reference Material

[1] Anubis Compound Registry • CAS N/A
[2] Operations Pulse • Marketed
[3] Risk Governance Ledger • LOW clearance for 2-5-LIDOCAINE-AND-2-5-PRILOCAINE

Enable JavaScript to finish loading this pageTurn on JavaScript in your browser and reload. For ordering help, email support@anubis.estate.

Loading your page…

Research Abstract

Anesthetic medication

2.5% LIDOCAINE AND 2.5% PRILOCAINE is a anesthetic asset inside marketed initiatives, optimized for therapeutic and clinical research.

The dossier currently sits in approved with a low risk rating, meaning it is cleared for baseline monitoring protocols.

Supply records cite CAS N/A with updates logged 2024-01-01.

2.5% LIDOCAINE AND 2.5% PRILOCAINE

Acquisition Protocol

Primary Vectors

Nomenclature

Reference Material

2.5% LIDOCAINE AND 2.5% PRILOCAINE